AstrinGyn

Generic name: ferric subsulfate
Dosage form: topical solution
Drug class:Miscellaneous coagulation modifiers

Medically reviewed by Drugs.com. Last updated on Oct 22, 2021.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

AstrinGyn®

(Ferric Subsulfate,Aqueous)

REF 6065

CONTENTS

Ferric subsulfate 259mg/g. Preserved with benzalkonium chloride 0.005%. Povidone USP 23.2%. Glycerin USP 13.3%. Purified Water USP.

AstrinGyn Description

AstrinGyn® (Ferric Subsulfate, Aqueous).

How is AstrinGyn Supplied

8 gm single-use glass bottles.

ACTIONS & USES

AstrinGyn® is a styptic agent used for achieving local hemostasis. In punch biopsies of the full dermis, the time to achieve hemostasis is typically less than 20 seconds.1 One method for applying ferric subsulfate solution for dermal use consists of the physician placing fingers at the opposite edges of the wound and stretching the skin. The wound is then wiped with gauze, the ferric subsulfate solution applied, and the tension maintained for approximately 15 seconds.2

Warnings

ForExternal Use Only. Should inadvertent ocular administration occur, the eye(s) should be washed immediately with large amounts of water or normal saline, occasionally lifting the upper and lower lids until no evidence of solution remains (approximately 15-20 minutes).

Precautions

As with all iron solutions applied to dermal surfaces denuded of epithelium or to mucous membranes, topical application of AstrinGyn® (ferric subsulfate) may result in hyperpigmentation (“tattooing”).3, 4

Microscopically, this hyperpigmentation may be observed as ferrugination of collagen fibers and fibrin.5 In one study of uterine cervical tissue, ferric subsulfate solution penetrated denuded mucosa and produced coagulation necrosis to a maximum depth of 0.6 mm.6In an in vitro study, ferric subsulfate solution produced ...